AML17 trial update FLT3ITD mutation and daunorubicin dosage

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=Ii-Wj7WxmyI

Nigel Russell, MD, from Nottingham University Hospitals NHS Trust, Nottingham, UK discusses the potential benefit of a higher dose of daunorubicin for a sub-...

Speaker: Nigel Russell, Subject: Acute Myeloid Leukemia, Event: BSH/ISH 2016, Format: Interview, Medicines: Daunorubicin, AML, FLT3-ITD mutation, ISRCTN78449203, Trial: AML17, Trial: AML19
#############################